De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: A United Kingdom National Cancer Research Institute trial

Journal of Clinical Oncology

Volumn 32, Issue 4, 2014, Pages 282-287

  Fields, Paul A ^a   Townsend, William ^b   Webb, Andrew ^e   Counsell, Nicholas ^b   Pocock, Christopher ^f   Smith, Paul ^b   Jack, Andrew ^g   El Mehidi, Nadjet ^b   Johnson, Peter W ^h   Radford, John ⁱ   Linch, David C ^c   Cunnningham, David ^d  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

^e Sussex Cancer Network   (United Kingdom)

^f KENT AND CANTERBURY HOSPITAL   (United Kingdom)

^g ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^h SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

ⁱ CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GEMCITABINE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; MONOCLONAL ANTIBODY;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; AORTA ANEURYSM; ARTICLE; BLOOD TOXICITY; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR ACCIDENT; CHEMOTHERAPY INDUCED ANEMIA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DIABETES MELLITUS; DIARRHEA; DRUG FEVER; FATIGUE; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; HYPERTENSION; INFECTION; ISCHEMIC HEART DISEASE; LARGE CELL LYMPHOMA; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PULMONARY HYPERTENSION; RISK FACTOR; THROMBOCYTOPENIA; VALVULAR HEART DISEASE; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; HEART STROKE VOLUME; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; UNITED KINGDOM;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; CYCLOPHOSPHAMIDE; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREAT BRITAIN; HEART DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISOLONE; SEVERITY OF ILLNESS INDEX; STROKE VOLUME; TREATMENT OUTCOME; VINCRISTINE;

EID: 84897019433     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.49.7586     Document Type: Article

References (18)

1. Yancik R, Ries LA: Cancer in older persons: An international issue in an aging world. Semin Oncol 31:128-136, 2004 (Pubitemid 38481234)
2. Mora O, Zucca E: Management of elderly patients with hematological neoplasms. Ann Oncol 18:i49-i53, 2007 (suppl 1)
3. Hershman DL, McBride RB, Eisenberger A, et al: Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol 26:3159-3165, 2008
4. Feugier P, Van Hoof A, Sebban C, et al: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117-4126, 2005 (Pubitemid 46211317)
5. Coiffier B, Lepage E, Briere J, et al: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242, 2002 (Pubitemid 34438862)
6. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006 (Pubitemid 46638950)
7. Pfreundschuh M, Schubert J, Ziepert M, et al: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol 9:105-116, 2008
8. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979 (Pubitemid 10218041)
9. Ng M, Waters J, Cunningham D, et al: Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma. Br J Cancer 92:1352-1357, 2005 (Pubitemid 40704999)
10. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI-sponsored international working group. J Clin Oncol 17:1244, 1999
11. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
12. Hans CP, Weisenburger DD, Greiner TC, et al: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004 (Pubitemid 38029949)
13. Janssen-Heijnen ML, van Spronsen DJ, Lemmens VE, et al: A population-based study of severity of comorbidity among patients with non-Hodgkin's lymphoma: Prognostic impact independent of International Prognostic Index. Br J Haematol 129:597-606, 2005 (Pubitemid 40825820)
14. Lyman GH, Delgado DJ: Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer 98:2402-2409, 2003 (Pubitemid 37466655)
15. Chao NJ, Rosenberg SA, Horning SJ: CEPP(B): An effective and well-tolerated regimen in poor-risk, aggressive non-Hodgkin's lymphoma. Blood 76:1293-1298, 1990
16. Moccia A, Schaff K, Hoskins P, et al: R-CHOP with etoposide substituted for doxorubicin (R-CEOP): Excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines. Blood 114, 2009 (abstr 408)
17. Luminari S, Montanini A, Caballero D, et al: Non-pegylated liposomal doxorubicin (MyocetTM) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): Results from the phase II EUR018 trial. Ann Oncol 21:1492-1499, 2010
18. Peyrade F, Jardin F, Thieblemont C, et al: Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: A multicentre, single-arm, phase 2 trial. Lancet Oncol 12:460-468, 2011